Editorial: Prostate cancer genomics: Application at different stages of a patient's journey

Front Oncol. 2022 Nov 29:12:1101678. doi: 10.3389/fonc.2022.1101678. eCollection 2022.

Darren M C Poon^{1

2}, Arun Azad³, Elena Castro⁴, Ravindran Kanesvaran⁵, Oliver Sartor⁶

¹ Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
² Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China.
³ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁴ Genitourinary Cancer Translational Research Group, Institute of Biomedical Research in Málaga, Málaga, Spain.
⁵ Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
⁶ Tulane Cancer Center, Tulane University Medical School, New Orleans, LA, United States.

No abstract available

Keywords: BRCA; ctDNA; genetic testing; histone lysine methylation; microenvironment; molecular targeted therapy; prostate cancer.

Publication types